MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy

[1] Burstein HJ(2021)Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Ann Oncol 32 1216-1235

[2] Curigliano G(2021)Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial JAMA Oncol 7 1654-1663

[3] Thürlimann B(2020)Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial JAMA Oncol 6 1355-1362

[4] Weber WP(2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 1796-1804

[5] Poortmans P(2018)Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival "early on" in neoadjuvant treatment of breast cancer Cancer Imaging 18 12-55

[6] Regan MM(2016)Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL Radiology 279 44-722

[7] Senn HJ(2022)Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 20 691-1385

[8] Winer EP(2018)MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 trial AJR Am J Roentgenol 210 1376-247

[9] Gnant M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-57

[10] Symmans WF(2021)Single cell genetic profiling of tumors of breast cancer patients aged 50 years and older reveals enormous intratumor heterogeneity independent of individual prognosis Cancers (Basel) 13 3366-116

[1] Burstein HJ(2021)Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Ann Oncol 32 1216-1235

[2] Curigliano G(2021)Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial JAMA Oncol 7 1654-1663

[3] Thürlimann B(2020)Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial JAMA Oncol 6 1355-1362

[4] Weber WP(2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 1796-1804

[5] Poortmans P(2018)Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival "early on" in neoadjuvant treatment of breast cancer Cancer Imaging 18 12-55

[6] Regan MM(2016)Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL Radiology 279 44-722

[7] Senn HJ(2022)Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 20 691-1385

[8] Winer EP(2018)MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 trial AJR Am J Roentgenol 210 1376-247

[9] Gnant M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-57

[10] Symmans WF(2021)Single cell genetic profiling of tumors of breast cancer patients aged 50 years and older reveals enormous intratumor heterogeneity independent of individual prognosis Cancers (Basel) 13 3366-116